Welcome to our dedicated page for HARVARD BIOSCIENCE SEC filings (Ticker: HBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harvard Bioscience filings document regulatory disclosures for a life science research tools company with Cellular and Molecular Technologies and Preclinical product families. Form 8-K reports cover operating results, preliminary financial information, corporate presentations, restructuring and manufacturing consolidation actions, executive employment agreements, and stockholder votes affecting the company’s common stock.
Proxy statements describe board matters, executive compensation, pay-versus-performance data, equity awards, charter amendments and special-meeting proposals, including reverse stock split authority and related voting results. The filings also frame governance, capital-structure and forward-looking disclosure topics tied to the company’s global sales channels and manufacturing footprint.
Harvard Bioscience, Inc. reported higher revenue but continued losses for the quarter ended June 30, 2026. Quarterly revenues rose to $22.7 million, up 11.1% year over year, driven mainly by increased sales to CROs in the Americas and distributors in Asia-Pacific. Gross profit grew to $12.6 million, though gross margin dipped slightly to 55.6% on less favorable product mix.
The company recorded a quarterly net loss of $2.9 million (loss per share $0.64), compared with a $2.3 million loss a year earlier, and a six‑month net loss of $6.3 million. There was no goodwill impairment in 2026 versus a $48.0 million non‑cash charge in the prior‑year period. Operating expenses increased as sales, marketing, and R&D headcount and travel normalized, and restructuring costs were incurred.
Balance sheet quality remains constrained: cash and cash equivalents were $6.5 million against long‑term debt of $36.7 million with an effective interest rate of 17.6% for the first half. Stockholders’ equity declined to $7.4 million. The company completed a 1‑for‑10 reverse stock split, leaving 4,552,305 shares outstanding as of August 4, 2026. Management is executing "Project Viking" and a sales and marketing restructuring, expecting combined annual cost savings of up to $4 million from 2028, with estimated restructuring charges of $4.0–5.0 million.
Harvard Bioscience, Inc. outlines its strategy as a translational science tools company and provides recent financial and capital structure updates. For FY25, the company reports $87 million revenue, 58% adjusted gross margin, $8 million adjusted EBITDA, and 54% recurring revenue, with a stated path toward 60%+ recurring revenue.
For 2Q26, revenue is $22 million, with adjusted EBITDA $1.7 million and an adjusted EBITDA margin of 7.3%, while GAAP results show a net loss and negative operating margin. FY26 guidance calls for 3%–5% revenue growth (raised from 2%–4%), 57%–59% gross margin (updated from 58%–60%), and 6%–10% adjusted EBITDA growth.
The company highlights a $40 million debt refinancing with BroadOak, including $7 million in convertible notes, extending debt maturity to 2029 and targeting about $3 million in annual cash savings. A manufacturing consolidation project, including phased closure of the Holliston, MA plant and headquarters move to Minneapolis, is expected to add approximately $3 million to adjusted EBITDA in 2027 and $4 million annually from 2028.
Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, up 11.1% from $20.5 million a year earlier, with foreign exchange contributing about 1 percentage point. GAAP gross margin was 55.6%, slightly below 56.4% last year, while non-GAAP gross margin was 56.7%.
The company recorded a Q2 2026 net loss of $2.9 million (basic and diluted loss per share of $0.64) versus a $2.3 million loss in Q2 2025. Adjusted EBITDA rose to $1.7 million from $1.5 million. For the six months ended June 30, 2026, revenue was $43.5 million, up from $42.2 million, and GAAP gross margin improved to 57.2% from 56.2%.
Six‑month net loss narrowed to $6.3 million from $52.6 million, primarily because 2025 included a $48.0 million goodwill impairment. Operating cash flow for the first half was negative $0.3 million versus positive $5.7 million a year earlier. At June 30, 2026, cash and cash equivalents were $6.5 million, debt was $36.7 million, and net debt was $33.5 million, with stockholders’ equity of $7.4 million.
Eade Katherine A. reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Katherine A. Eade received an award of 16,556 restricted stock units of common stock at no cost. The RSUs vest in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first. After this grant, she beneficially owns 58,669 shares, including 42,113 shares of common stock adjusted for a 10-for-1 reverse stock split that took effect on March 13, 2026.
Snider William reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director William Snider received an equity grant in the form of 16,556 restricted stock units of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first, providing time-based compensation for board service.
After this grant, Snider holds a total of 48,556 common share equivalents, including the new award, previously purchased common shares from March 16 and March 17, 2026, and 11,000 restricted stock units scheduled to fully vest on December 17, 2026. The filing also notes that the 11,000 restricted stock units were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.
DENELSKY STEPHEN J reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Stephen J. Denelsky received a grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.
After this award, Denelsky holds 37,556 shares and RSUs in total, including 10,000 shares of common stock purchased on March 17, 2026 and 11,000 RSUs scheduled to fully vest on September 5, 2026. The filing notes that these 11,000 RSUs were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.
Gagnon Robert E. reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Robert E. Gagnon received an equity grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.
After this grant, Gagnon beneficially owns 27,556 common shares, including 11,000 shares previously issued upon vesting of earlier RSUs. Those 11,000 shares were adjusted to reflect a 10-for-1 reverse stock split of Harvard Bioscience common stock that took place on March 13, 2026.
Benson Seth Benjamin reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Seth Benjamin Benson received a grant of 16,556 restricted stock units of common stock, awarded at a price of $0.0000 per share. This equity award will vest in full immediately before the company’s next annual meeting or one year from the grant date, whichever comes first.
After this grant, Benson directly holds 27,556 shares of common stock, including the new award and 11,000 shares already beneficially owned. The filing also notes a 10-for-1 reverse stock split of Harvard Bioscience common stock that occurred on March 13, 2026, which adjusted previously reported award amounts.
Harvard Bioscience, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an Amended and Restated 2021 Incentive Plan that increases the shares of common stock reserved for equity awards by 400,000 shares, on top of 646,520 shares that were available for future awards as of December 31, 2025.
Stockholders also approved an amendment to the Employee Stock Purchase Plan to increase authorized shares for employee purchases, elected two Class II directors to terms ending in 2029, ratified Grant Thornton LLP as independent auditor for 2026, and backed executive compensation in a non-binding advisory vote.
Harvard Bioscience reported a Schedule 13G/A amendment showing that Adam M. Hutt, as Managing Member of Leviticus Partners, beneficially owns 293,676 shares of Common Stock, representing 6.5% of the class. The filing lists sole voting and sole dispositive power over those shares.
The document provides the filer’s and issuer’s addresses and the CUSIP 416906105. A signature line shows the amendment signed on 05/14/2026.